The National Pharmaceutical Council has announced Purdue Pharma as its newest member, and that Dr. Tracy Mayne, head of Medical Affairs Strategic Research at Purdue Pharma, will serve as his company’s representative on the NPC Board of Directors.

“I am pleased to welcome Purdue Pharma and Dr. Mayne to NPC,” said NPC President Dan Leonard. “Dr. Mayne brings a wealth of expertise in medical affairs and health policy development that will be an invaluable resource in our efforts to further address issues such as the conduct and application of real-world evidence and the shift toward high-value, patient-centered care. We look forward to Dr. Mayne’s participation on our Board.”

The NPC Board of Directors consists of a representative from each member company.

“NPC’s research and activities are helping to drive the discussion around the importance of defining value as patients seek care centered on their needs,” said Dr. Mayne. “Purdue Pharma welcomes the opportunity to work with NPC and other member companies to advance the conversation on ensuring patient access to high-value care and improving the efficiency and effectiveness of our health care delivery systems.”

In becoming an NPC member, Purdue Pharma joins with other leading research-based pharmaceutical companies, including AbbVie, Allergan, Amgen, Astellas Pharma U.S., AstraZeneca, Bayer HealthCare Pharmaceuticals, Biogen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck & Co., Novartis Pharmaceuticals, Pfizer, Sanofi, Takeda Pharmaceuticals USA and Teva Pharmaceuticals.

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the U.S. that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients.